GSK rotavirus vaccine gets committee review
Executive Summary
GlaxoSmithKline's rotavirus vaccine Rotarix is scheduled for review by the Vaccines and Related Biological Products Advisory Committee Feb. 20. Over two consecutive seasons, Rotarix was more effective at preventing against rotavirus than Merck's RotaTeq, but GSK's vaccine fared worse at preventing severe cases. The product class has a history of safety concerns as well - Wyeth's RotaShield was withdrawn in 1999 due to safety concerns of intestinal blockage, and the label for Merck's RotaTeq was changed over incidence of intussusception as well in February 2007...
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.